Source: Brazilian journal of medical and biological research. Unidade: FM
Subjects: ANTINEOPLÁSICOS, BIOFARMACOLOGIA, NEOPLASIAS, ANTICORPOS, FÁRMACOS IMUNOSSUPRESSORES
ABNT
FERNANDES, G. S. et al. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC). Brazilian journal of medical and biological research, v. 51, n. 3, 2018Tradução . . Disponível em: https://doi.org/10.1590/1414-431X20177214. Acesso em: 03 nov. 2024.APA
Fernandes, G. S., Sternberg, C., Lopes, G., Chammas, R., Gifone, M. A. C., Gil, R. A., & Araujo, D. V. (2018). The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC). Brazilian journal of medical and biological research, 51( 3). doi:10.1590/1414-431X20177214NLM
Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifone MAC, Gil RA, Araujo DV. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC) [Internet]. Brazilian journal of medical and biological research. 2018 ; 51( 3):[citado 2024 nov. 03 ] Available from: https://doi.org/10.1590/1414-431X20177214Vancouver
Fernandes GS, Sternberg C, Lopes G, Chammas R, Gifone MAC, Gil RA, Araujo DV. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC) [Internet]. Brazilian journal of medical and biological research. 2018 ; 51( 3):[citado 2024 nov. 03 ] Available from: https://doi.org/10.1590/1414-431X20177214